A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Cancer

Protocol
10-226
Full Title
A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Phase
II
Purpose

Everolimus and bevacizumab are two drugs already approved for treating advanced renal cell carcinoma, a serious form of kidney cancer. In this study, researchers are evaluating the safety and effectiveness of using both drugs together in patients with advanced non-clear cell renal cell cancer. The hope is that both drugs together may be more effective than either drug alone.

Everolimus is an oral drug that inhibits a molecule called mTOR, which helps cancer cells grow. Bevacizumab inhibits the formation of blood vessels that tumors need to grow and spread. It is given intravenously (by vein).

Investigator
Molina, Ana Maria, MD
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced non-clear cell renal cell cancer.
  • Patients may not have previously received sunitinib, sorafenib, bevacizumab, sirolimus, temsirolimus, everolimus, or deforolimus.
  • At least 4 weeks must have passed since any major surgery or radiation therapy and entry into the study.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Martin Voss at 646-422-4631.

Disease(s)
Kidney Cancer
Related Diseases

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »